CytomX Therapeutics (CTMX) Non-Current Assets (2014 - 2026)

CytomX Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 47.24% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $33.4 million (down 40.43% YoY), and the FY2025 full-year result was $7.6 million, down 42.21% from the prior year.
• Non-Current Assets for Q1 2026 stood at $6.3 million, down from $7.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $28.4 million in Q1 2022, with the low at $6.3 million in Q1 2026.
• Historically, Non-Current Assets has averaged $17.4 million across 5 years, with a median of $17.4 million in 2024.
• The largest YoY upside for Non-Current Assets was 16.89% in 2022 against a maximum downside of 79.87% in 2022.
• CytomX Therapeutics' Non-Current Assets stood at $23.8 million in 2022, then retreated by 20.74% to $18.9 million in 2023, then retreated by 29.85% to $13.2 million in 2024, then sank by 42.21% to $7.6 million in 2025, then retreated by 18.09% to $6.3 million in 2026.
• The last three Non-Current Assets figures came in at $6.3 million (Q1 2026), $7.6 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.